Clinical Effect of Anti-Pd-1 Antibody on Gut Microbiota in Patients with Advanced Colorectal Cancer
PI Hongquan
LIU Huifang
ZHU Hanhan
YANG Meng
Abstract：Objective To investigate the effect of anti-programmed death protein-1(PD-1)antibody in the treatment of patients with advanced colorectal cancer,and its impact on gut microbiota.Method A total of 50 patients with advanced colorectal cancer admitted to the Sixth Affiliated Hospital of Jinan University were included in the study.The enrollment pe-riod was concentrated from March 2022 to March 2023.According to the random number table method,they were divided into the control group and the observation group.The control group,with 23 patients included,received routine treatment,and the observation group,with 27 patients included,received anti PD-1 antibody on the basis of the control group.The changes of immune function,tumor marker levels,intestinal microbiota,and intestinal barrier function between the two groups before and after treatment,and to compare the short-term disease control rates between the two groups.Results The immune func-tion indicators,intestinal microbiota content,and intestinal barrier function indicators of the two groups after treatment were all better than those before treatment,and the difference was statistically significant(P＜0.05);The CD4+,CD8+,CD4+/CD8+,Escherichia coli,Bifidobacterium,Lactobacillus,Diamine Oxidase,Bacterial Endotoxins,and D-lactate values of the patients in the observation group were better than those in the control group,and the difference was statistically significant(P＜0.05).The levels of glycoprotein antigen 125,carbohydrate antigen 199,and carcinoembryonic antigen in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The short-term disease control rate in the observation group was higher than that in the control group(88.89％vs 65.22％),and the difference was statistically sig-nificant(P＜0.05).Conclusion Anti-PD-1 antibody Cindilimab injection has a significant clinical effect in the treatment of advanced colorectal cancer,Enhancing the immune system,correcting gut microbiota imbalance,and repairing intestinal barrier function.
Keywords：Anti PD-1 antibodyCindilimabColorectal cancerIntestinal microbiotaIntestinal barri-er function
Publication Date：2024-10-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1489-1493 )